Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 8, Issue 1, 2006, Pages 110-115

  Bell, David S H ^a,b   Ovalle, F ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b Faculty Office Tower   (United States)

Author keywords

Beta cell preservation; Glycaemic control; Thiazolidinediones; Triple oral therapy; Type 2 diabetes; Weight gain

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C PEPTIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; METFORMIN; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY WEIGHT DISORDER; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DISEASE COURSE; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; FOLLOW UP; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN SYNTHESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PANCREAS ISLET BETA CELL; PROSPECTIVE STUDY; STAGING; TREATMENT OUTCOME; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 33645963777     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2005.00560.x     Document Type: Article

References (24)

1. Ovalle F, Bell DSH. Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocr Pract 1998; 4: 64-65.
2. Bell DSH, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract 2002; 8: 370-372.
3. Bell DSH, Ovalle F. How long can insulin be avoided in the patient with type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea? Endocr Pract 2000; 6: 293-295.
4. Ovalle F, Bell DSH. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2002; 4: 56-59.
5. Bell DSH. B-cell rejuvenation with thiazolidinediones. Am J Med 2003; 115 (Suppl. 8A): 20S-23S.
6. Bell DSH, Ovalle F, Shadmany S. Conversion from troglitazone to rosiglitazone. Endocr Pract 2001; 7: 326.
7. Ovalle F, Bell DSH. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care 2004; 27: 2585-2589.
8. Tiikkainen M, Hukkinen A-M, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effect of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169-2176.
9. Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo controlled trial. Ann Intern Med 2001; 134: 737-745.
10. Palumbo PJ. The case for insulin treatment early in type 2 diabetes. Cleve Clin J Med 2004; 71: 385-386, 391-392, 394.
11. Dailey GE III, Noor MA, Park JS, Bruce S, Fiedorek FT. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: A randomized, double-blind trial. Am J Med 2004; 116: 276-278.
12. Bell DSH, Mayo MS. Weight loss in patients treated with a metformin-sulfonylurea combination in comparison with twice daily mixed insulin. Endocr Pract 1998; 4: 360-366.
13. Poulson MK, Henricksen JE, Hother-Nielsen O, Beck-Neilsen H. The combined effect of triple therapy with rosiglitazone, metformin and insulin as part in type 2 diabetic patients. Diabetes Care 2003; 26: 3273-3279.
14. Deroza G, Cicero AF, Gaddi A et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind randomized, controlled, parallel-group trial. Clin Ther 2004; 26: 744-754.
15. UKPDS Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
16. Kelly IE, Han TS, Walsh K et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288-293.
17. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA 2000; 284: 1384-.
18. Gomez-Perez FJ, Fanghanel-Salmon G, Antonio-Barbosa J et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002; 18: 127-134.
19. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
20. Strowig SM, Aviles-Santa ML, Raskin P. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 2004; 27: 1577-1583.
21. Reynolds LR, Konz EC, Frederich RC, Anderson JW. Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus. Diabetes Obes Metab 2002; 4: 270-275.
22. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003; 115 (Suppl. 8A): 42S-48S.
23. Asnani S, Richard BC, Desouza C, Fonseca V. Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet. Curr Med Res Opin 2003; 19: 609-613.
24. Viberti G, Kahn S, Green DA. A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25: 1737-1743.